Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 11/20 | 0.63 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2259392 | 0.88 | HCRTR2 (0.81) | HCRTR2HCRTR1PKMMCOLN3POLB | |
| SCHEMBL2259690 | 0.88 | PKM (0.62) | HCRTR2HCRTR1PKMMCOLN3POLB | |
| SCHEMBL2259676 | 0.82 | HCRTR2 (0.59) | HCRTR2HCRTR1PKMKEAP1NFE2L2 | |
| SCHEMBL2262072 | 0.81 | HCRTR2 (0.79) | HCRTR2HCRTR1PKMKEAP1NFE2L2 | |
| SCHEMBL2259402 | 0.79 | HCRTR2 (0.69) | HCRTR2HCRTR1 | |
| SCHEMBL2258679 | 0.77 | HCRTR2 (0.53) | HCRTR2HCRTR1PKMMCOLN3POLB | |
| SCHEMBL8989976 | 0.77 | PKM (0.60) | HCRTR2HCRTR1PKMMCOLN3POLB | |
| SCHEMBL8989962 | 0.75 | PKM (0.58) | HCRTR2HCRTR1PKMMCOLN3POLB | |
| SCHEMBL2258870 | 0.75 | HCRTR2 (0.78) | HCRTR2HCRTR1PKMKEAP1NFE2L2 | |
| SCHEMBL4867331 | 0.73 | HCRTR2 (0.62) | HCRTR2HCRTR1PKMMCOLN3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003654-B2 | N-glycinsulfonamide derivatives and uses as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-11-05 | — | — | US | disclosed |
| EP-2007717-A1 | NOVEL SULFONAMIDE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116374-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | HCRTR2, HCRTR1, NPSR1 | HCRTR2 1/4885HCRTR1 2/4885PKM 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.